KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EBITDA (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed EBITDA for 13 consecutive years, with -$3.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 70.38% to -$3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$33.5 million through Dec 2025, up 51.94% year-over-year, with the annual reading at -$33.5 million for FY2025, 51.94% up from the prior year.
  • EBITDA hit -$3.7 million in Q4 2025 for Arbutus Biopharma, up from -$7.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $2.5 million in Q2 2025 to a low of -$24.6 million in Q1 2025.
  • Historically, EBITDA has averaged -$16.1 million across 5 years, with a median of -$18.1 million in 2022.
  • Biggest five-year swings in EBITDA: plummeted 39.05% in 2021 and later soared 112.68% in 2025.
  • Year by year, EBITDA stood at -$21.5 million in 2021, then grew by 0.25% to -$21.4 million in 2022, then grew by 11.99% to -$18.8 million in 2023, then skyrocketed by 33.27% to -$12.6 million in 2024, then surged by 70.38% to -$3.7 million in 2025.
  • Business Quant data shows EBITDA for ABUS at -$3.7 million in Q4 2025, -$7.7 million in Q3 2025, and $2.5 million in Q2 2025.